Chelsea Therapeutics to Present at the Oppenheimer 20th Annual Healthcare Conference...

* Reuters is not responsible for the content in this press release.

Tue Oct 27, 2009 7:31am EDT 

Chelsea Therapeutics to Present at the Oppenheimer 20th Annual Healthcare
Conference on Wednesday, November 4, 2009

CHARLOTTE, N.C., Oct. 27, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Oppenheimer
20th Annual Healthcare Conference at 1:00 PM on Wednesday, November 4, 2009 at
the Waldorf Astoria Hotel in New York.

Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, will provide a
brief overview of the company's product pipeline, clinical development status
and upcoming milestones.

Dr. Pedder's presentation will be webcast live and archived for 90 days on
Chelsea's website, www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires
and develops innovative products for the treatment of a variety of human
diseases. Chelsea's most advanced drug candidate, Droxidopa, is an orally active
synthetic precursor of norepinephrine initially being developed for the
treatment of neurogenic orthostatic hypotension. In addition to Droxidopa,
Chelsea is also developing a portfolio of metabolically inert oral antifolate
molecules engineered to have potent anti-inflammatory and anti-tumor activity to
treat a range of immunological disorders, including two clinical stage product
candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior
safety and tolerability, as well as increased potency versus methotrexate (MTX).

This press release contains forward-looking statements regarding future events.
These statements are just predictions and are subject to risks and uncertainties
that could cause the actual events or results to differ materially. These risks
and uncertainties include our need to raise operating capital, our history of
losses, risks and costs of drug development, risk of regulatory approvals, our
reliance on our lead drug candidates Droxidopa and CH-1504, reliance on
collaborations and licenses, intellectual property risks, competition, market
acceptance for our products if any are approved for marketing and reliance on
key personnel including specifically Dr. Pedder.

-0-
CONTACT:  Chelsea Therapeutics 
          Investors:
          Kathryn McNeil
          718-788-2856
          mcneil@chelseatherapeutics.com

          Hill & Knowlton 
          Media:
          Sean Leous
          212-885-0549
          sean.leous@hillandknowlton.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.